Mitochondrial Probe Methyltriphenylphosphonium (TPMP) Inhibits the Krebs Cycle Enzyme 2-Oxoglutarate Dehydrogenase

Moustafa Elkalaf1,4, Petr Tůma2,4, Martin Weiszenstein3,4, Jan Polák3,4, Jan Trnka1,2,4*

1 Laboratory for Metabolism and Bioenergetics, Third Faculty of Medicine, Charles University, Prague, Czech Republic, 2 Department of Biochemistry, Cell and Molecular Biology, Third Faculty of Medicine, Charles University, Prague, Czech Republic, 3 Department of Sport Medicine, Third Faculty of Medicine, Charles University, Prague, Czech Republic, 4 Centre for Research on Diabetes, Metabolism and Nutrition, Third Faculty of Medicine, Charles University, Prague, Czech Republic

* jan.trnka@lf3.cuni.cz

Abstract

Methyltriphenylphosphonium (TPMP) salts have been widely used to measure the mitochondrial membrane potential and the triphenylphosphonium (TPP+) moiety has been attached to many bioactive compounds including antioxidants to target them into mitochondria thanks to their high affinity to accumulate in the mitochondrial matrix. The adverse effects of these compounds on cellular metabolism have been insufficiently studied and are still poorly understood. Micromolar concentrations of TPMP cause a progressive inhibition of cellular respiration in adherent cells without a marked effect on mitochondrial coupling. In permeabilized cells the inhibition was limited to NADH-linked respiration. We found a mixed inhibition of the Krebs cycle enzyme 2-oxoglutarate dehydrogenase complex (OGDHC) with an estimated IC50 3.93 [3.70–4.17] mM, which is pharmacologically plausible since it corresponds to micromolar extracellular concentrations. Increasing the lipophilic character of the used TPP+ compound further potentiates the inhibition of OGDHC activity. This effect of TPMP on the Krebs cycle ought to be taken into account when interpreting observations on cells and mitochondria in the presence of TPP+ derivatives. Compounds based on or similar to TPP+ derivatives may also be used to alter OGDHC activity for experimental or therapeutic purposes.

Introduction

Triphenylphosphonium (TPP+) cations have been widely used in the study of mitochondria [1], particularly as probes in the measurement of the mitochondrial membrane potential (mainly methyltriphenylphosphonium salts, TPMP) in isolated mitochondria respiring on succinate [2–4]. In the past decade a number of TPP+ derivatives with significant chemical and
biological activities have been prepared and used with diagnostic and therapeutic intentions, such as MitoQ, MitoTEMPOL, MitoE, MitoSOD, MitoSOX, MitoB [5–10].

The work of Ross et al. confirmed that the uptake of TPMP follows the Nernst equation Eq (1) with a resultant $\Delta \psi$-dependent accumulation inside mitochondria [11].

$$\Delta \psi = \frac{RT}{zF} \ln \left( \frac{[\text{TPMP}^+]_{\text{out}}}{[\text{TPMP}^+]_{\text{in}}} \right)$$

Therefore, the accumulation of a monovalent positively charged species such as TPMP$^+$ inside a negatively charged compartment at 37°C is given as:

$$[\text{TPMP}^+]_{\text{in}} = \frac{[\text{TPMP}^+]_{\text{out}}}{C_2} \times 10^{-\Delta \psi/61.5}$$

This corresponds to an approximate ten-fold higher concentration in the cytoplasm with respect to the extracellular space when the plasma membrane potential ($\Delta \psi_p$) is $-60$ mV and another approximate 100-fold accumulation inside the inner mitochondrial compartment with respect to the cytoplasm when the mitochondrial membrane potential ($\Delta \psi_m$) is $-120$ mV.

The net result is an approximate 1000-fold accumulation of TPMP inside the mitochondrial matrix compared to the extracellular concentration (Fig 1). $\Delta \psi_m$ value varies continuously depending on several factors including the cellular consumption of ATP [12]. The exact concentration of TPMP inside mitochondria hence varies according to changes in $\Delta \psi_p$ and $\Delta \psi_m$ but it is possible to estimate an approximate concentration in the mitochondrial matrix to be in the millimolar range when the concentration of TPMP in the extracellular space ranges within the micromolar range.

It has been previously observed that some TPP$^+$ derivatives exert effects on mitochondrial metabolism [13–15] due to non-specific binding to membranes, such as the potentiation of proton leak across the inner mitochondrial membrane, which is largely independent of the biologically-active moiety but become more pronounced with increasing hydrophobicity of the molecule [16]. The observed inhibitory effect of TPMP on cellular respiration of MES-13 [17] cells indicates that there may be another mechanism of action of TPMP in addition to proton leak. In order to study the effects of TPP$^+$ compounds in more detail, we investigated the respiratory response to TPMP in intact cells using the Seahorse XF analyzer [18] and in cells with selectively permeabilized plasma membrane [19] in the presence of various mitochondrial

---

extracellular 1 μM

| cytoplasm ≈10 μM | $\Delta \psi_p$ ≈ – 60 mV |
|-----------------|--------------------------|
| $\Delta \psi_m$ ≈ –120 mV |
| mitochondrion ≈ 1000 μM |

Fig 1. A schematic illustrates TPMP distribution. Due to the membrane potential, lipophilic cations tend to achieve Nernstian equilibrium across biological membranes.
substrates in order to pinpoint, if possible, the specific enzymatic sites of TPMP action. Our results confirmed the previous observation of Reilly et al. [17] and suggested that the inhibitory effect cannot be entirely explained by an interference with mitochondrial membranes or inhibition of respiratory complexes. We therefore investigated the effects of three alkyl-TPP⁺ derivatives on the pyruvate dehydrogenase complex and several other Krebs cycle enzymes and discovered a specific inhibitory effect of TPMP on 2-oxoglutarate dehydrogenase complex (OGDHC). Our study provides a new insight into the inhibitory effect of TPMP and other similar compounds on cellular respiration previously observed in intact cells [17] and in studies with isolated mitochondria [20,21].

Experimental procedures

Materials

All chemicals were purchased from Sigma-Aldrich unless stated otherwise.

Animal care and handling

Wistar rats were obtained from AnLab Ltd., Prague, Czech Republic. The rats were housed in plastic cages (2-4/animals/cage) with free access to food and water and natural light/dark cycle and handled daily to check health status. Animals were euthanized with diethylether overdose prior to tissue isolation. Animal handling and sacrifice took place in a certified animal facility according to principles of laboratory animal care (NIH publication no. 85–23, revised 1985).

Collection of rat tissues

Three rats 13–15 weeks old weighing 200–300 g were sacrificed. We collected both gastrocnemii muscles to prepare a homogenate enriched in mitochondrial fraction, which was approved for this study by the Committee for Protection of Laboratory Animals of the Third Faculty of Medicine, Charles University in Prague.

Preparation of muscle homogenate enriched in mitochondrial fraction

We prepared the homogenate by modifying a previously described protocol [22]. A freshly removed rat gastrocnemius was washed three times by ice-cold buffer (250 mM sucrose, 5 mM Tris, 1 mM EGTA, 0.1% fatty acid free BSA, pH 7.4) then flash frozen in liquid nitrogen, and stored at -80°C. On the preparation day, we removed the visible fat and connected tissue by a scalpel blade, and then the muscle was finely dissected into small fragments in a glass dish on ice. The muscle pieces were diluted 1:10 in ice-cold muscle homogenization medium (250 mM sucrose, 20 mM Tris, 40 mM KCl, 2 mM EGTA, pH 7.4) then the suspension was transferred to a glass tube and chopped with an UltraTurrax blender followed by homogenisation in a Dounce homogeniser with a motor-driven Teflon plunger at 500 r.p.m (≈ 10 passes). The homogenate was then centrifuged for 15 min at 600 ×g at 4°C. The supernatant was transferred into new tubes on ice then flash frozen in liquid nitrogen and stored at −80°C. Protein concentration in the homogenate was determined using the BCA assay.

Cell culture conditions

C2C12 cells were obtained from Sigma-Aldrich and grown in Dulbecco-modified Eagle’s medium (DMEM, Life Technologies) containing 1 g/l D-glucose to enhance mitochondrial respiration [23], 4 mM L-glutamine and 1 mM sodium pyruvate, and supplemented with 10% fetal bovine serum, 100 unit/ml penicillin and 100 μg/ml streptomycin. All cultures were
incubated at 37°C in a humidified atmosphere containing 5% CO₂ and 95% air. Cells were subcultured every 48 hours.

Analysis of metabolism in intact cells

Cellular respiration of intact C2C12 cells was measured using the XF-24 analyzer (Seahorse Bioscience). We performed mitochondrial bioenergetic assays based on published protocols [18]. The XF assay medium (bicarbonate-free modified DMEM, Seahorse Bioscience) was supplemented with 4 mM L-glutamine, 1 mM pyruvate, and 1 g/l D-glucose. The pH was adjusted with 1 M NaOH to 7.4 at 37°C. Cells were seeded at a density of 20,000 cells per well and left overnight to attach and proliferate to obtain a monolayer of cells before measurement. After measuring the basal respiration, TPMP or vehicle (deionized H₂O) were injected and a mitochondrial respiration test was performed by sequential additions of 1 μM oligomycin, 0.5 μM carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP) and 1 μM rotenone and antimycin A.

Analysis of metabolism in permeabilized cells

We assayed respiratory activity in permeabilized C2C12 myoblast using the Seahorse XF-24 analyzer by modifying a published protocol [19]. Cells were seeded as previously mentioned. The mitochondrial assay solution (MAS) contained 70 mM sucrose, 220 mM mannitol, 10 mM KH₂PO₄, 5 mM MgCl₂, 2 mM HEPES, 1 mM EGTA, 0.2% BSA, and 4 mM ADP. The pH was adjusted with 10 M KOH to 7.4 at 37°C. The used substrates included 5 mM pyruvate/ 2.5 mM malate, 5 mM glutamate/ 2.5 mM malate or 10 mM succinate and 10 μM rotenone. Cellular permeabilization was performed using the XF plasma membrane permeabilizer reagent (XF-PMPR, Seahorse Biosciences) at a final concentration of 1 nM prior to the measurement. After measuring OCR in basal state, 10 μM TPMP or vehicle (deionized H₂O) were injected, followed by injection of 0.5 μM FCCP and 1 μM antimycin A.

Enzymatic activity

The activity of enzymes was assayed spectrophotometrically using TECAN Infinite M200Pro microplate reader. To find the site of inhibition, we assayed all enzymes in a homogenate enriched in mitochondrial fraction prepared from rat skeletal muscle except the pyruvate dehydrogenase complex, which was obtained purified (Sigma P7032) due to high interference of lactate dehydrogenase in the homogenate even after inhibition with sodium oxamate. Prior to enzymatic assays this homogenate was exposed to three cycles of rapid freeze- thaw. In assays where the absorbance of NADH was followed, 10 μM rotenone and 1 μM antimycin A were added to block the activity of respiratory chain complexes. We modified the published protocols mainly to fit the assays in the microplate reader. To study the kinetics of OGDHC and the activity of its components, we used the purified OGDHC enzyme (Sigma K1502).

**Pyruvate dehydrogenase complex (PDHC).** Using the provider’s protocol, in assay mixture containing 50 mM Tris (pH 7.4), 0.2 mM MgCl₂, 10 μM CaCl₂, 2 mM NAD⁺, 2.6 mM L-cysteine, 0.12 mM coenzyme A sodium, 2.5 mM L-carnitine, 0.3 mM thiamine pyrophosphate, 1 mM sodium pyruvate and 0.005 U/ml pyruvate dehydrogenase. A₃₄₀ was followed for 3 min at 30°C.

**Citrate synthase (CS).** As previously described [22], in assay mixture containing 100 mM Tris (pH 8), 0.1% Triton X-100, 0.1 mM 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB), 0.3 mM acetyl coenzyme A trilithium and 0.5 mM freshly prepared sodium oxalacetate. A₄₁₂ was followed for 3 min at 30°C.

**NAD⁺ dependent isocitrate dehydrogenase (IDH).** Using a modified protocol [24], in assay mixture containing 70 mM Tris-acetate (pH 7.6), 0.1% Triton X-100, 0.1 mM EDTA,
10 μM rotenone, 1 μM antimycin A, 2.5 mM MnCl₂, 0.8 mM NAD⁺, 1 mM ADP, 1 mM DTT and 8 mM trisodium isocitrate. A₃₄₀ was followed for 3 min at 30°C.

**2-Oxoglutarate dehydrogenase complex (OGDHC).** Using a modified protocol [25], in assay mixture containing 100 mM Tris (pH 8), 0.1% Triton X-100, 0.1 mM EDTA, 10 μM rotenone, 1 μM antimycin A, 2 mM MgCl₂, 2 mM CaCl₂, 0.8 mM NAD⁺, 2 mM DL-Dithiothreitol (DTT), 0.5 mM coenzyme A sodium, 0.1 mM thiamine pyrophosphate and 2 mM 2-oxoglutarate monobasic. A₃₄₀ was followed for 3 min at 30°C.

**Glutamate dehydrogenase (GDH).** Using a modified protocol [26], in assay mixture containing 100 mM Tris (pH 9.1), 0.1% Triton X-100, 10 μM rotenone, 1 μM antimycin A, 1 mM CaCl₂, 2 mM CaCl₂, 0.5 mM NAD⁺ and 10 mM glutamate. A₃₄₀ was followed for 5 min at 30°C.

**Malate dehydrogenase (MDH).** Using a modified protocol [25], in assay mixture containing 100 mM (pH 8) Tris, 0.1% Triton X-100, 0.1 mM EDTA, 10 μM rotenone, 1 μM antimycin A, 2.5 mM MgCl₂, 0.8 mM NAD⁺, 1 mM DTT, 0.3 mM acetyl CoA trilithium and 10 mM sodium malate. Acetyl CoA was added to accelerate the elimination of oxaloacetate to obtain a linear reaction. A₃₄₀ was followed for 3 min at 30°C.

**Complex I.** Using a modified protocol [27], in assay mixture composed of 25 mM potassium phosphate (pH 7.8), 3.5 g/l BSA, 2 mM EDTA, 60 μM 2,6-dichloroindophenol (DCIP), 70 μM decylubiquinone, 1 μM antimycin A and 10 mM glutamate. A₆₀₀ was followed for 3 min at 37°C. Rotenone sensitive activity was calculated by subtracting the activity of wells treated with 10 μM rotenone.

**Complex II.** Using a modified protocol [27], in assay mixture containing 80 mM potassium phosphate (pH 7.8), 1 g/l BSA, 2 mM EDTA, 10 mM succinate, 80 μM DCIP, 50 μM decylubiquinone, 1 μM antimycin A and 3 μM rotenone. A₆₀₀ was followed for 3 min at 37°C. Malonate sensitive activity was calculated by subtracting the activity of wells treated with 20 mM malonate.

**Complex III.** According to [28], in assay mixture containing 25 mM potassium phosphate (pH 7.5), 50 μM ferricytochrome c, 4 mM sodium azide, 0.1 mM EDTA, 0.025% Tween 80 and 50 μM decylubiquinol. A₅₅₀ was followed for 3 min at 37°C. Antimycin A sensitive activity was calculated by subtracting the activity of wells treated with 10 μM antimycin A. Decylubiquinol was prepared by dissolving decylubiquinone in acidified ethanol (pH 4), then few grains of sodium borohydride (NaBH₄) were added followed by vortexing until the solution became colorless [29].

**Complex IV.** As previously described [30], in assay buffer containing 30 mM potassium phosphate (pH 7.4) and 25 μM of freshly prepared ferrocytochrome c. A₅₅₀ was followed for 3 min at 37°C. The absorbance of samples oxidised with 10 μl of 0.5 M potassium hexacyanoferrate(III) was subtracted from all measurements, then the natural logarithm of absorbance was plotted against time and compared to untreated control. Ferrocyanochrome c was freshly prepared by adding few grains of sodium dithionite to 1 mM stock of ferrocyanochrome c.

**Purified OGDHC enzyme studies.** We used purified OGDHC to study the effect of TPMP on OGDHC kinetics using Michaelis-Menten model and the impact on each component of the complex. We incubated purified OGDHC in reaction mixture containing different concentrations of TPMP (0, 0.5, 1, 1.5, 2, 3, 4, 5 mM) and induced the reaction by adding different concentrations of 2-oxoglutarate (0, 0.05, 0.1, 0.25, 0.5, 1 mM). We concluded the values of Vmax and Km by non-linear curve fit and then plotted these values against TPMP concentrations to visualize the relationship between Vmax or Km and TPMP concentration. We followed that with a linear regression analysis.

The activity of OGDHC was measured according to the provider’s protocol in assay mixture containing 50 mM Tris (pH 7.4), 0.2 mM MgCl₂, 10 μM CaCl₂, 2 mM NAD⁺, 2.6 mM l-
cysteine, 0.12 mM coenzyme A sodium, 0.3 mM thiamine pyrophosphate, 0.005 U/ml OGDHC and sodium 2-oxoglutarate monobasic. $A_{340}$ was followed for 3 min at 30°C. We assayed the enzymatic activity of individual components of OGDHC as previously described [31]. E1 component (alpha-ketoglutarate dehydrogenase) was assayed in 35 mM KH$_2$PO$_4$ (pH 7.5), 0.5 mM EDTA, 0.5 mM MgSO$_4$, 0.1 mM DCIP, 1 mM thiamine pyrophosphate, 0.1 U/ml OGDHC and 2 mM sodium 2-oxoglutarate monobasic. $A_{600}$ was followed for 3 min at 30°C. E2 component (dihydrolipoyl transsuccinylase) was assayed in 35 mM KH$_2$PO$_4$ (pH 7.5), 0.5 mM EDTA, 0.1 mM DTNB, 0.1 U/ml OGDHC and 0.1 mM succinyl coenzyme A sodium. $A_{412}$ was followed for 3 min at 30°C. E3 component (dihydrolipoyl dehydrogenase) was assayed in 35 mM KH$_2$PO$_4$ (pH 7.5), 0.5 mM EDTA, 0.3 NADH, 0.1 U/ml OGDHC and 0.4 mM lipoamide. $A_{340}$ was followed for 3 min at 30°C.

**Metabolite level determination**

Determination of low molecular organic acids was performed by a capillary electrophoretic procedure combined with a highly sensitive contactless conductivity detection as previously described [32,33]. The cells were trypsinized then centrifuged and resuspended in serum free medium, then treated with 10 μM TPMP or vehicle deionized H$_2$O in suspension (≈ 4 million cells) with continuous gentle shaking for one hour in a water bath at 37°C. Cells were then centrifuged and samples from the supernatant were obtained for analysis of extra-cellular lactate. The rest of supernatant was discarded and the pellet was extracted to 100 μl 75% acetonitrile/water $\nu/\nu$ and vigorously vortexed. The mixture was centrifuged at 5000 ×g at 4°C, then the supernatant was carefully taken to measure citric acid and 2-oxoglutaric acid. All electrophoretic measurements were carried out using the HP3DCE system (Agilent Technologies, Waldbronn Germany) in an uncoated fused silica capillary (Composite Metal Services, UK), inner diameter 25 μm, outer diameter 360 μm, total length 31.5 cm, length to detector 18 cm. 2-Oxoglutaric acid was determined in the optimized background electrolyte of 50 mM citric acid + 2% $\nu/\nu$ polyethylene glycol (PEG, M$_r$ 8000) dissolved in 50% $\nu/\nu$ acetonitrile, pH 2.5; at a separation voltage/current -30 kV/-2.5 μA. Electrophoretic separation of citric and lactic acids was carried out in the background electrolyte of 20 mM N-cyclohexyl-2-aminoethanesulfonic acid (CHES)/NaOH, pH 9.5; at a separation voltage/current +30 kV/+6 μA.

**Detection of changes in mitochondrial membrane potential $\Delta \psi_m$**

Qualitative changes in $\Delta \psi_m$ were determined as the changes in tetramethylrhodamine methyl ester (TMRM) fluorescence in C2C12 myoblasts [34,35]. Cells were seeded in a 96 well plate (≈ 30,000 cells/well) and left to attach over night. After careful washing and to perform the measurement in the non-quench mode [36], cells were incubated with 10 nM TMRM and the relevant treatment for 45 minutes at 37°C in serum-free, phenol red-free DMEM (Life technologies) supplemented with 4 mM L-glutamine, then washed with medium containing 0.2% fatty acid free BSA, and incubated again for 5 minutes before bottom TMRM fluorescence was measured with TECAN Infinite M200Pro microplate reader (ex 520 ±9 nM, em 580 ±20 nM) at 37°C.

**Statistical analyses**

Data are presented as mean [95% confidence interval (CI)]. Student’s t-test with alpha level set to 0.05 or one-way ANOVA with Tukey’s multiple comparisons test were performed using GraphPad Prism version 6.0d for Mac OS X, GraphPad Software, La Jolla California USA, [www.graphpad.com](http://www.graphpad.com). We used the same program for the regression analysis and curve fitting to estimate IC$_{50}$, Vmax and Km values. Differences found statistically significant are marked with an asterisk. The number of independent experiments is denoted as n.
Results

TPMP inhibits mitochondrial respiration in intact cells

An acute exposure to TPMP caused a gradual decrease in oxygen consumption rate in intact C2C12 cells respiring on glucose, glutamine and pyruvate in a dose-dependent manner (Fig 2A). The corresponding increase in the extracellular acidification rate was indicative of anaerobic glycolysis (Fig 2B). The extent of the decrease in respiration was time-dependent, which was demonstrated by the time-dependent shift in the IC50 from 4.84 μM after 20 minutes to reach 0.87 μM after 60 minutes (Fig 2C). TPMP inhibited mainly mitochondrial ATP synthesis-driven respiration (S1 Fig), the IC50 for this parameter was found to be 0.79 μM (Fig 2D).

Removing the regulatory function of ATP synthase by uncoupling with FCCP caused a rise in the IC50 to be 3.37 μM (extracellular) presumably due to the leak of TPMP from mitochondria following the collapse of membrane potential (Fig 2E).

The inhibitory effect on respiration makes it difficult to assess TPMP-induced proton leak by an analysis for respiration alone. Therefore we decided to measure mitochondrial

---

Fig 2. TPMP inhibits mitochondrial respiration and increases glycolytic activity in intact C2C12 cells. A. Metabolic analysis of cellular respiration in intact C2C12 myoblasts. Cells were treated with different TPMP concentrations or vehicle (deionized H2O), followed by a sequential injection of 1 μM oligomycin (O), 1 μM FCCP (F), then 1 μM rotenone and antimycin A (R+A) mixture. The TPMP treated cells showed a decrease in oxygen consumption rate (OCR) following the TPMP addition. The inhibitory effect following TPMP treatment is demonstrated by a gradual dose-dependent decrease in cellular OCR. Data is expressed as the percentage of basal OCR (OCR%) and is presented as means ±95% CI, n = 4, measured in triplicate. B. A corresponding increase in ECAR following TPMP addition. Data is expressed as the percentage of basal ECAR (ECAR%) and is presented as means ±95% CI, n = 4, measured in triplicate. C. IC50 shift showing the time dependent inhibition after 20, 40, and 60 minutes of TPMP treatment. D. IC50 for mitochondrial ATP driven respiration represents difference between respiration after oligomycin addition and respiration in the steady state, which includes proton leak respiration. E. An increase in IC50 of uncoupled respiration following the induced collapse of membrane potential by FCCP and the leak of the accumulated TPMP inside mitochondria. In C, D & E mitochondrial OCR was calculated by subtracting non-mitochondrial respiration after rotenone-antimycin A treatment, then the values were plotted against logarithm values of TPMP in micromolar concentration (log TPMP μM vs. normalized response %). IC50 was then estimated by non-linear regression analysis. F. Detection of changes in Δψ induced by 10 μM TPMP and mitochondrial inhibitors expressed as changes in TMRM fluorescence (ex = 520 nm and em = 580 nm). We perturbed mitochondrial respiration by different inhibitors to induce different states of membrane polarization. The groups included an untreated control (polarized), 1 μM oligomycin treated (hyperpolarized), 0.5 μM FCCP treated (depolarized) and 1 μM rotenone treated (decreased polarization). Data is expressed as TMRM fluorescence (a.u) means ±95% CI, n = 4, in which each group included 10 wells. *, p = 0.0013; #, p = 0.0004; **, p<0.0001; ###, p = 0.0076; ns, not significant.
membrane potential using a membrane-permeable cationic fluorophore. When we compared the effect of TPMP with other mitochondrial inhibitors on $\Delta \psi_m$, we found that TPMP caused a decrease in $\Delta \psi_m$ but not as much as the protonophore FCCP that causes complete collapse of membrane potential. The ATP synthase inhibitor oligomycin induced a hyperpolarization, as expected. The complex I inhibitor rotenone (Fig 2F) caused a similar decrease in membrane potential as TPMP, in this case by decreasing the influx of electrons into the respiratory chain, which suggests a similar action by TPMP.

Inhibition of NADH-linked respiration in permeabilized cells

We then studied the effects of TPMP in cells with permeabilized plasma membrane, which allowed us to use a wider range of respiratory substrates that fit differently into mitochondrial metabolism, namely pyruvate/malate and glutamate/malate, which feed into the Krebs cycle and via complex I into the respiratory chain, and succinate, which is metabolized solely by the respiratory complex II (Fig 3).

In permeabilized C2C12 myoblasts, an exposure to 10 $\mu$M TPMP (approximate equivalent of 1 $\mu$M TPMP extracellular concentration in the presence of plasma membrane potential due to Nernstian accumulation) caused a rapid decrease of respiration on pyruvate/malate to 26.17% [23.21–29.12%] and of glutamate/malate respiration to 26.08% [24.66–27.50%] of basal respiration (Fig 4). When succinate was used as a substrate, the respiratory rate following a TPMP addition decreased only slightly to 89.17% [87.54–90.79%]. Adding an uncoupler (FCCP) caused only a moderate increase in respiration, which corresponds well to previous studies in permeabilized cells [37,38]. The inhibition of respiration was associated with an increase in the proton production rate (PPR, analogous to ECAR in intact cells).

![Fig 3. A schematic presentation of Krebs cycle showing the active enzymes when different mitochondrial substrates are used. NADH produced is re-oxidized by the respiratory complex I. The role of malate in pyr/mal respiration is to provide oxaloacetate that is further metabolized to citrate in the presence of acetyl-CoA. In glu/mal respiration, malate takes part in the malate aspartate shuttle. PDHC, pyruvate dehydrogenase complex; A-CoA, acetyl-CoA; CS, citrate synthase; C, citrate; ACN, aconitase; IC, isocitrate; IDH, isocitrate dehydrogenase; GDH, glutamate dehydrogenase; 2-OG, 2-oxoglutarate; OGDHC, 2-oxoglutarate dehydrogenase complex; S-CoA, succinyl-CoA; SCS, succinyl-CoA synthase; S, succinate; SDH, succinate dehydrogenase; F, fumarate; FH, fumarate hydratase; M, malate; MDH, malate dehydrogenase; OA, oxaloacetate; Q, ubiquinone; QH$_2$, ubiquinol.](https://doi.org/10.1371/journal.pone.0161413.g003)
Mechanism of the inhibitory effect of TPMP—respiratory and metabolic enzymes

Since the previous set of experiments showed a site of inhibition upstream of complex II, we studied the activity of mitochondrial enzymes exposed to 1 mM TPMP (approximate equivalent of 1 μM extracellular TPMP, once again assuming about 1000-fold accumulation due to membrane potential). We observed negligible inhibition of respiratory chain complexes and most enzymes of the Krebs cycle, however, there was a significant inhibition of the OGDHC (Fig 5A). When treated with 1 mM TPMP, the activity of OGDHC was reduced to 77.00% [70.34–83.66%] of the untreated control. The IC50 of TPMP was estimated to be 3.93 [3.70–4.17] mM (Fig 5B).

More hydrophobic TPP+ derivatives cause stronger inhibition of OGDHC

We also tested two longer alkyl chain TPP+ derivatives with respect to OGDHC inhibition in muscle homogenate enriched in mitochondrial fraction: 1 mM propyl-TPP+ reduced the activity to 60.70% [60.09–61.31%] of the untreated control, while pentyl-TPP+ caused even more inhibition to reach 15.87% [12.44–19.30%] of the control activity. Increasing the length of the alkyl side chain therefore appears to enhance the inhibitory effect on OGDHC activity (Fig 5C). Activities of pyruvate dehydrogenase complex and other Krebs cycle enzymes were not affected by the more hydrophobic TPP+ moieties (S2 Fig).
Metabolite analysis

The level of extracellular lactate increased in the TPMP treated cells (Fig 5D), which supports the increase in the ECAR observed with the analysis of metabolism (Fig 1B). The analysis of intracellular metabolites showed an accumulation of 2-oxoglutarate in the TPMP treated cells further supporting the hypothesis of TPMP inhibiting OGDHC also in intact cells. There was an ≈ 2-fold increase in the level of 2-oxoglutarate (Fig 5E), while there were negligible changes...
in the citrate level ruling out a general toxic effect. This increase in the 2-oxoglutarate/citrate ratio is indicative of the inhibition of Krebs cycle and the shift towards anaerobic glycolysis.

**TPMP causes mixed inhibition of the OGDHC complex**

In order to determine the type of inhibition of TPMP, we plotted the values of Vmax and Km (Fig 6A) assuming the Michaelis-Menten kinetics in the presence of different TPMP concentrations. We found a high correlation between Vmax and TPMP ($R^2 = 0.91$), and significant correlation between Km and TPMP ($R^2 = 0.69$). The pattern of decreasing Vmax and increasing Km fits in a mixed-inhibition model.

**TPMP has little effect on OGDHC components**

We also measured the effect of TPMP on the activity of the three components of OGDHC (Fig 6B). The activity of E1 component (alpha-ketoglutarate dehydrogenase, EC 1.2.4.2) was unaffected by 1 mM and only slightly reduced by a 5 mM concentration of TPMP. The activity of the E2 component (dihydrolipoyl transsuccinylase, EC 2.3.1.61) was actually increased in the presence of TPMP and the activity of E3 component (dihydrolipoyl dehydrogenase, EC 1.8.1.4) was not significantly affected.

**Cationic detergents exhibit similar inhibitory action as TPMP**

Due to the hydrophobic nature of TPP$^+$ derivatives, we were also interested whether similar detergents have similar effects. The cationic detergent benzylidodecyl(dimethyl)ammonium (BDDA) exhibited a dose-dependent inhibitory action on OGDHC (Fig 6C), while the non-ionic detergent Triton-X100 caused an actual increase in OGDHC activity, as previously observed [39].
Discussion

Triphenylphosphonium derivatives are widely used to study mitochondria and to influence its various functions including the production of reactive oxygen species [40]. The specific effects of derivatives such as MitoQ, MitoTEMPO or MitoSOD have been well studied [5,6,8], other effects due to their chemical structure [41], however, are much less understood. Lipophilic triphenylphosphonium cations are known to interfere with mitochondrial membrane structures and respiratory chain complexes [42–44] due to their high affinity to the phospholipid membranes [45] and in this paper we show that some of the simplest and most widely used TPP+ derivatives also inhibit the Krebs cycle.

Our data from intact cells show a general inhibitory effect of TPMP on cellular respiration, which is considerably slower to develop compared to more lipophilic derivatives we tested previously [16]. In permeabilized cells this inhibition is much faster, probably due to an easier transport of relatively hydrophilic TPMP across the permeabilized plasma membrane [11]. Interestingly, there is a striking difference in the extent of inhibition depending on the respiratory substrate used: succinate respiration requiring only functional respiratory chain complexes II, III and IV is inhibited only to a negligible extent, while respiration on pyruvate/malate and glutamate/malate, which requires also other Krebs cycle enzymes (plus pyruvate dehydrogenase in case of pyruvate and glutamate dehydrogenase in case of glutamate) decreases substantially on exposure to TPMP. This led us to investigate further, which of these enzymes could be the site of inhibition by triphenylphosphonium derivatives.

A more detailed study of enzyme activities led to a clear candidate for the target enzyme–2-oxoglutarate dehydrogenase complex (OGDHC), which oxidises and decarboxylates 2-oxoglutarate and attaches coenzyme A to the product to form succinyl-CoA [46,47]. We estimated the IC50 to be in the milimolar range, which appears high compared to other inhibitory substances, however, we must keep in mind the fact that due to the negative plasma/mitochondrial membrane potentials TPMP and its analogues can be expected to accumulate about least thousand-fold compared to their extracellular concentrations. It is therefore clear that an exposure to micromolar concentrations of TPMP and its derivatives will cause a substantial inhibition of a key Krebs cycle enzyme.

We were also interested in the type of inhibition caused by TPMP. Our kinetic analysis suggests mixed inhibition with the inhibitor binding both to the enzyme and the enzyme-substrate complex. Since the OGDHC comprises three individual subunits we were interested if TPMP affects any or all of them. Our finding that individual subunits are affected much less than the intact complex raises a question about the possible molecular mechanism through which TPMP exerts its inhibitory effect.

Alkyl TPP+ derivatives as lipophilic cations are similar in physicochemical properties to widely used cationic detergents (e.g. alkylammonium salts). Our observation that the cationic detergent BDDA also causes an inhibition of OGDHC while the non-ionic detergent Triton X actually increases the activity of the enzyme complex suggests a possible similarity of action between the two cationic lipophilic species.

An intriguing question arises when one compares results presented here to our previous study [16], which showed only a modest inhibitory effect of propylTPP+ on intact cell respiration. Why propylTPP+ is a more potent OGDHC inhibitor than TPMP but causes less inhibition in intact cells? One possible explanation could be that the concentration of the significantly more hydrophobic propylTPP+ in the mitochondrial matrix, where it is needed to interfere with OGDHC, would be lower than that of TPMP due to its preferential association with mitochondrial membranes.
Our data show for the first time that the simplest TPP⁺ derivative TPMP and its more hydrophobic analogues are inhibitors of the Krebs cycle enzyme OGDHC most likely through the disruption of the enzyme complex. This finding should be taken into account when interpreting data from experiments using TPP⁺ salts. It also opens up new research opportunities into the possibility of manipulating Krebs cycle fluxes and intramitochondrial and intracellular availability of its intermediates such as 2-oxoglutarate.

**Supporting Information**

**S1 Fig.** TPMP inhibits cellular respiration in adherent cells. The respiratory parameters concluded from measuring cellular respiration in intact C2C12 myoblasts after treatment with different concentrations of TPMP or vehicle (deionized H₂O), followed by a sequential injection of 1 μM oligomycin, 1 μM FCCP, then 1 μM rotenone and antimycin A (R+A) mixture. ATP turnover-driven respiration is calculated by subtracting respiration after oligomycin from basal respiration (basal—oligomycin treated). Maximum respiratory capacity is calculated by subtracting the residual respiration after rotenone and antimycin A treatment from the FCCP induced respiration (uncoupled respiration—non mitochondrial respiration). H⁺ leak is calculated as the difference between the respiration after oligomycin addition and the residual respiration after rotenone and antimycin A treatment (oligomycin respiration—non mitochondrial respiration). Data is expressed as the percentage of basal OCR (OCR%) and is presented as means ±95% CI, n = 4, measured in triplicate. (TIF)

**S2 Fig.** Longer chain alkyl-TPP⁺ compounds have a higher inhibitory effect on OGDHC. The enzymatic activities of pyruvate dehydrogenase complex, glutamate dehydrogenase and other Krebs cycle enzymes were not affected by 1 mM concentration of the more lipophilic TPP⁺ moieties in the assay mixture, except the OGDHC, which was significantly reduced. Data is presented as means ±95% CI, n = 3. Respiratory chain complexes were not altered by alkyl-TPP⁺ with chains ranging from C3 to C7 [16]. PDHC, pyruvate dehydrogenase complex; CS, citrate synthase; IDH, isocitrate dehydrogenase; OGDHC, 2-oxoglutarate dehydrogenase complex; MDH, malate dehydrogenase; GDH, glutamate dehydrogenase. TPMP, methyltriphenylphosphonium; Propyl, propyltriphenylphosphonium; Pentyl, pentyltriplphenylphosphonium. (TIF)

**Author Contributions**

**Conceptualization:** JT ME.

**Formal analysis:** ME JT PT.

**Funding acquisition:** JT.

**Investigation:** ME PT JT.

**Methodology:** JT ME PT MW.

**Project administration:** JT.

**Resources:** PT.

**Supervision:** JT JP.

**Visualization:** ME JT.
Writing - original draft: ME JT.
Writing - review & editing: ME JT JP PT MW.

References

1. Ross MF, Kelso GF, Blaikie FH, James AM, Cochemé HM, Filipovska A, et al. Lipophilic triphenylphosphonium cations as tools in mitochondrial bioenergetics and free radical biology. Biochem. 2005; 70: 222–230. doi: 10.1038/sj.bj.3605145-5

2. Liberman EA, Topal V, Tsafina LM, Jasaitis AA, Skulachev VP. Mechanism of coupling of oxidative phosphorylation and the membrane potential of mitochondria. Nature. 1969; 222: 1076–1078. doi: 10.1038/2221076a0 PMID: 578094

3. Grinius LL, Jasaitis AA, Kadziauskas YT, Liberman EA, Skulachev VP, Topali VP, et al. Conversion of biomembrane-produced energy into electric form. I. Submitochondrial particles. Biochim Biophys Acta. 1970; 216: 1–12. doi: 10.1016/0005-2728(70)90156-8 PMID: 4395700

4. Brown GC, Brand MD. Thermodynamic control of electron flux through mitochondrial cytochrome bc1 complex. Biochim. 1985; 225: 399–405. PMID: 2983670

5. Kelso GF, Porteous CM, Coulter CV, Hughes G, Porteous WK, Ledgerwood EC, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. J Biol Chem. 2001; 276: 4588–4596. doi: 10.1074/jbc.M009093200 PMID: 11092892

6. Trnka J, Blaikie FH, Logan A, Smith RAJ, Murphy MP. Antioxidant properties of MitoTEMPOL and its hydroxylamine. Free Radic Res. 2009; 43: 4–12. doi: 10.1080/10715760802582183 PMID: 19058062

7. Smith RAJ, Porteous CM, Coulter CV, Murphy MP. Selective targeting of an antioxidant to mitochondria. Eur J Biochem. 1999; 263: 709–716. doi: 10.1046/j.1432-1327.1999.00543.x PMID: 10469134

8. Kelso GF, Maroz A, Cochemé HM, Logan A, Prime TA, Peskin AV, et al. A mitochondria-targeted macrocyclic Mn(II) superoxide dismutase mimetic. Chem Biol. 2012; 19: 1237–1246. doi: 10.1016/j.chembiol.2012.08.005 PMID: 23102218

9. Robinson KM, Janes MS, Pehar M, Monette JS, Ross MF, Hagen TM, et al. Selective fluorescent imaging of superoxide in vivo using ethidium-based probes. Proc Natl Acad Sci U S A. 2006; 103: 15038–15043. doi: 10.1073/pnas.1003194103 PMID: 17015830

10. Cochemé HM, Logan A, Prime TA, Abakumova I, Quin C, McQuaker SJ, et al. Using the mitochondria-targeted ratiometric mass spectrometry probe MitoB to measure H2O2 in living Drosophila. Nat Protoc. 2012; 7: 946–958. doi: 10.1038/nprot.2012.035 PMID: 22517261

11. Ross MF, Prime TA, Abakumova I, James AM, Porteous CM, Smith RAJ, et al. Rapid and extensive uptake and activation of hydrophobic triphenylphosphonium cations within cells. Biochem J. 2008; 411: 633–645. doi: 10.1042/BJ20080063 PMID: 18294140

12. Lee I, Bender E, Arnold S, Kadenbach B. New control of mitochondrial membrane potential and ROS formation-a hypothesis. Biol Chem. 2001; 382: 1629–1636. doi: 10.1515/BC.2001.198 PMID: 11843176

13. Severin FF, Severina II, Antonenko YN, Rokitskaya TI, Cherepanov DA, Mokhova EN, et al. Penetrating cation/fatty acid anion pair as a mitochondria-targeted protonophore. Proc Natl Acad Sci U S A. 2010; 107: 663–668. doi: 10.1073/pnas.0910216107 PMID: 20080732

14. Pločitá-Hlavatá L, Ježek J, Ježek P. Pro-oxidant mitochondrial matrix-targeted ubiquinone MitoQ10 acts as anti-oxidant at retarded electron transport or proton pumping within Complex I. Int J Biochem Cell Biol. 2009; 41: 1697–1707. doi: 10.1016/j.biocel.2009.02.015 PMID: 19433311

15. Antonenko YN, Khailova LS, Knorre DA, Mokhova O V, Rokitskaya TI, Ilyasova TM, et al. Penetrating Cations Enhance Uncoupling Activity of Anionic Protonophores in Mitochondria. PLoS One. 2013; 8: e61902. doi: 10.1371/journal.pone.0061902 PMID: 23626747

16. Trnka J, Elkala M, Andél M. Lipophilic Triphenylphosphonium Cations Inhibit Mitochondrial Electron Transport Chain and Induce Mitochondrial Proton Leak. PLoS One. 2015; 10: e0121837. doi: 10.1371/journal.pone.0121837 PMID: 25927690

17. Reily C, Mitchell T, Chacko BK, Benavides GA, Murphy MP, Darley-Usmar VM. Mitochondrially targeted compounds and their impact on cellular bioenergetics. Redox Biol. Elsevier; 2013; 1: 86–93. doi: 10.1016/j.redox.2012.11.009

18. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol. 2007; 292: 125–136. doi: 10.1152/ajpcell.00247.2006
19. Salabei JK, Gibb AA, Hill BG. Comprehensive measurement of respiratory activity in permeabilized cells using extracellular flux analysis. Nat Protoc. Nature Publishing Group; 2014; 9: 421–438. doi: 10.1038/nprot.2014.018

20. Brand MD. Measurement of mitochondrial protonomotive force. Bioenergetics—A practical approach. New York: Oxford University Press Inc.; 1995. pp. 39–62.

21. Ojovan SM, Knorre DA, Markova O V, Smirnova EA, Bakeeva LE, Severin FF. Accumulation of dodecyltriphenylphosphonium in mitochondria induces their swelling and ROS-dependent growth inhibition in yeast. J Bioenerg Biomembr. 2011; 43: 175–180. doi: 10.1007/s10863-011-9345-8 PMID: 21360288

22. Spinazzi M, Casarin A, Pertegato V, Salvati L, Angelini C. Assessment of mitochondrial respiratory chain enzymatic activities on tissues and cultured cells. Nat Protoc. 2012; 7: 1235–1246. doi: 10.1038/nprot.2012.058 PMID: 22653162

23. Elkalaf M, Andéil M, Trnka J. Low glucose but not galactose enhances oxidative mitochondrial metabolism in C2C12 myoblasts and myotubes. PLoS One. 2013; 8: e70772. doi: 10.1371/journal.pone.0070772 PMID: 23940640

24. Chen RF, Plaut GW. Activation and Inhibition of Dpn-Linked Isocitrate Dehydrogenase of Heart By Certain Nucleotides. Biochemistry. 1963; 2: 1023–1032. doi: 10.1021/bi4311501 PMID: 14087354

25. Goncalves S, Paupe V, Dassa E, Briere JJ, Favier J, Gimenez-Roqueplo AP, et al. Rapid determination of tricarboxylic acid cycle enzyme activities in biological samples. BMC Biochem. 2010; 11: 5. doi: 10.1186/1471-2091-11-5 PMID: 20109171

26. Fricke W, Pahlich E. Malate: A possible source of error in the NAD glutamate dehydrogenase assay. J Exp Bot. 1992; 43: 1515–1518. doi: 10.1093/jxb/43.11.1515

27. Janssen A, Trijbels F, Sengers R, Smeitink J, Heuvel L, Wintjes L, et al. Spectrophotometric Assay for Complex I of the Respiratory Chain in Tissue Samples and Cultured Fibroblasts. Clin Chem. 2007; 53: 729–734. PMID: 17332151

28. Luo C, Long J, Liu J. An improved spectrophotometric method for a more specific and accurate assay of mitochondrial complex III activity. Clin Chim Acta. 2008; 395: 38–41. doi: 10.1016/j.cca.2008.04.025 PMID: 18502205

29. Trounce IA, Kim YL, Jun AS, Wallace DC. Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitchondrial cell lines. Methods Enzymol. 1996; 264: 484–509. S0076-6879(96)64044-0 [pii] PMID: 8965721

30. Cooperstein SJ, Lazarow A. A microspectrophotometric method for the determination of cytochrome oxidase. J Biol Chem. 1951; 189: 665–670. PMID: 14832284

31. Sauer SW, Okun JG, Schwab M a., Cmic LR, Hoffmann GF, Goodman SI, et al. Bioenergetics in glutaryl-coenzyme A dehydrogenase deficiency: A role for glutaryl-coenzyme A. J Biol Chem. 2005; 280: 21830–21836. doi: 10.1074/jbc.M502845200 PMID: 15840571

32. Tůma P, Máliková K, Samcová E, Štulík K. Rapid monitoring of arrays of amino acids in clinical samples using capillary electrophoresis with contactless conductivity detection. J Sep Sci. 2010; 33: 2394–2401. doi: 10.1002/jssc.201000137 PMID: 20535751

33. Tůma P, Samcová E, Štulík K. Determination of the spectrum of low molecular mass organic acids in urine by capillary electrophoresis with contactless conductivity and ultraviolet photometric detection-An efficient tool for monitoring of inborn metabolic disorders. Anal Chim Acta. 2011; 685: 84–90. doi: 10.1016/j.aca.2010.11.007 PMID: 21168555

34. Scaduto RC, Grotyohann LW. Measurement of mitochondrial membrane potential using fluorescent rhodamine derivatives. Biophys J. Elsevier; 1999; 76: 469–477. doi: 10.1016/S0006-3495(99)77214-0 PMID: 10379904

35. Floryk D, Houštěk J. Tetramethyl rhodamine methyl ester (TMRM) is suitable for cytofluorometric measurements of mitochondrial membrane potential in cells treated with digitonin. Biosci Rep. 1999; 19: 27–34. PMID: 10379904

36. Nicholls DG. Fluorescence measurement of mitochondrial membrane potential changes in cultured cells. Methods Mol Biol. 2012; 810: 119–133. doi: 10.1007/978-1-61779-382-0_8 PMID: 22057564

37. Rasmussen UF, Rasmussen HN. Human quadriceps muscle mitochondria: a functional characterization. Mol Cell Biochem. 2000; 208: 37–44. PMID: 10939626

38. Johnson G, Reusell D, Dumas J-F, Douay O, Malthiery Y, Simard G, et al. Influence of intensity of food restriction on skeletal muscle mitochondrial energy metabolism in rats. Am J Physiol Endocrinol Metab. 2006; 291: E460–E467. doi: 10.1152/ajpendo.00258.2005 PMID: 16621897

39. Heckert LL, Butler MH, Reimers JM, Albe KR, Wright BE. Purification and characterization of the 2-oxoglutarate dehydrogenase complex from Dictyostelium discoideum. J Gen Microbiol. 1989; 135: 155–61. Available: http://www.ncbi.nlm.nih.gov/pubmed/2778429 PMID: 2778429

40. Smith RAJ, Hartley RC, Cochemé HM, Murphy MP. Mitochondrial pharmacology. Trends Pharmacol Sci. 2012; 33: 341–352. doi: 10.1016/j.tips.2012.03.010 PMID: 22621106
41. Asin-Cayuela J, Manas AB, James AM, Smith RAJ, Murphy MP. Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Lett. 2004; 571: 9–16. doi: 10.1016/j.febslet.2004.06.045 PMID: 15280009
42. O’Malley Y, Fink BD, Ross NC, Prisinzano TE, Sivitz WI. Reactive oxygen and targeted antioxidant administration in endothelial cell mitochondria. J Biol Chem. 2006; 281: 39766–39775. doi: 10.1074/jbc.M608268200 PMID: 17060316
43. Leo S, Szabadkai G, Rizzuto R. The mitochondrial antioxidants MitoE2 and MitoQ10 increase mitochondrial Ca2+ load upon cell stimulation by inhibiting Ca2+ efflux from the organelle. Ann N Y Acad Sci. 2008; 1147: 264–274. doi: 10.1196/annals.1427.019 PMID: 19076448
44. Trendeleva TA, Rogov AG, Cherepanov DA, Sukhanova EI, II'yasova TM, Severina II, et al. Interaction of tetraphenylphosphonium and dodecyltriphenylphosphonium with lipid membranes and mitochondria. Biochem. 2012; 77: 1021–1028. doi: 10.1134/S000629791209009X
45. Murphy MP. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol. 1997; 15: 326–330. doi: 10.1016/S0167-7799(97)01068-8 PMID: 9263481
46. Sheu KF, Blass JP. The alpha-ketoglutarate dehydrogenase complex. Ann N Y Acad Sci. 1999; 893: 61–78. PMID: 10672230
47. Qi F, Pradhan RK, Dash RK, Beard DA. Detailed kinetics and regulation of mammalian 2-oxoglutarate dehydrogenase. BMC Biochem. BioMed Central Ltd; 2011; 12: 53. doi: 10.1186/1471-2091-12-53